Similarly, in hepatocellular carcinoma (HCC), a serum-based metabolite panel was identified in metabolic syndrome-positive cases and was proposed as a diagnostic tool with improved accuracy compared with AFP [171]. This evidence concerns the gene AFP and metabolic syndrome.